Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
3,182,163
-
Total 13F shares
-
2,960,800
-
Share change
-
+600,000
-
Total reported value
-
$2,990,408
-
Price per share
-
$1.01
-
Number of holders
-
1
-
Value change
-
+$606,000
-
Number of buys
-
1
Institutional Holders of Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) as of Q4 2023
As of 31 Dec 2023,
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
2,960,800 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Versant Venture Management, LLC, Erste Asset Management GmbH, New Leaf Venture Partners, L.L.C., TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., MILLENNIUM MANAGEMENT LLC, and ACADIAN ASSET MANAGEMENT LLC.
This page lists
49
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.